Ads
related to: what is acute myeloid leukemia- Dosing & Monitoring
Twice Daily
Oral Dosing.
- Efficacy
Durable Complete Remissions
for R/R AML Patients.
- Mechanism of Action
Inhibits Mutant IDHI and
Restores Myeloblast Differentiation
- Safety
Learn More About Well Characterized
Safety Profile.
- Dosing & Monitoring
Search results
On National Historic Marker Day, meet the CNY man whose plaques celebrate history in 49 states
The Post-Standard· 8 hours agoAn imposing physical stature and a charisma to match, you would not know it to look at the self-made...
‘Potter Strong’ fundraiser in honor of the late Rochelle Potter
WFXR Roanoke via Yahoo Sports· 15 hours agoROANOKE, Va. (WFXR) — In a follow-up to a story we brought you back in January on Patrick Henry...
HanxBio announces the publication of a research paper in Scientific Reports on preclinical...
FOX 4 Kansas City· 4 days agoHanxBio today announced that it has published a research article titled "Narazaciclib, a novel...
Hemogenyx Pharmaceuticals outlines significant progress with HEMO-CAR-T in 2023
Proactive Investors· 4 hours agoAfter re-manufacturing the lentivirus, Hemogenyx successfully addressed the FDA's concerns and...
FDA grants breakthrough status for Kura Oncology's AML drug candicate By Investing.com
Investing.com· 4 days agoFood and Drug Administration (FDA) has awarded Breakthrough Therapy Designation to its drug...
Ipsen, Skyhawk to develop RNA-targeting pills for rare brain diseases
BioPharma Dive via Yahoo Finance· 4 days agoNonetheless, several have drawn the interest of large pharmaceutical companies. Ipsen, for instance,...
Why Big Pharma Is Following Novartis' Lead In A $25 Billion Market
Investor's Business Daily· 1 day agoThat could be why the first generation of radiopharmaceuticals were flops, Seth, the Actinium CEO,...
Kura Oncology Receives Breakthrough Therapy Designation for Ziftomenib in NPM1-Mutant AML
Morningstar· 4 days agoFood and Drug Administration (FDA) for the treatment of patients with relapsed/refractory (R/R) NPM1-mutant acute myeloid leukemia (AML ...
Is the FDA Pausing More Cancer Trials? It's Hard to Tell
Medscape· 3 days agoIs the FDA Pressing Pause on More Cancer Trials? In October, the US Food and Drug Administration...
Deverra Therapeutics Granted FDA Fast Track Designation for DVX101
Digital Journal· 2 days agoDesignation Validates Preliminary Data and Supports Accelerated Drug Development SEATTLE, WA / ACCESSWIRE / April 24, 2024 / Deverra Therapeutics, Inc., a clinical-stage biotechnology company ...
Ads
related to: what is acute myeloid leukemia